SCNI
Price
$1.42
Change
+$0.01 (+0.71%)
Updated
Sep 30 closing price
Capitalization
996.04K
Intraday BUY SELL Signals
VANI
Price
$1.24
Change
+$0.01 (+0.81%)
Updated
Sep 30 closing price
Capitalization
112.75M
49 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SCNI vs VANI

SCNI vs VANI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SCNI vs. VANI commentary
Oct 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCNI is a Buy and VANI is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
SCNI vs VANI: Fundamental Ratings
SCNI
VANI
OUTLOOK RATING
1..100
4770
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
12100
PRICE GROWTH RATING
1..100
9556
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCNI's Valuation (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for VANI (42) in the null industry. This means that SCNI’s stock grew somewhat faster than VANI’s over the last 12 months.

SCNI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as VANI (100) in the null industry. This means that SCNI’s stock grew similarly to VANI’s over the last 12 months.

SCNI's SMR Rating (12) in the Pharmaceuticals Major industry is significantly better than the same rating for VANI (100) in the null industry. This means that SCNI’s stock grew significantly faster than VANI’s over the last 12 months.

VANI's Price Growth Rating (56) in the null industry is somewhat better than the same rating for SCNI (95) in the Pharmaceuticals Major industry. This means that VANI’s stock grew somewhat faster than SCNI’s over the last 12 months.

SCNI's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as VANI (100) in the null industry. This means that SCNI’s stock grew similarly to VANI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCNIVANI
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 13 days ago
85%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 01, 2026
Stock price -- (SCNI: $1.42 vs. VANI: $1.24)
Brand notoriety: SCNI and VANI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SCNI: 15% vs. VANI: 48%
Market capitalization -- SCNI: $996.04K vs. VANI: $112.75M
SCNI [@Biotechnology] is valued at $996.04K. VANI’s [@Biotechnology] market capitalization is $112.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCNI’s FA Score shows that 2 FA rating(s) are green while VANI’s FA Score has 0 green FA rating(s).

  • SCNI’s FA Score: 2 green, 3 red.
  • VANI’s FA Score: 0 green, 5 red.
According to our system of comparison, SCNI is a better buy in the long-term than VANI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCNI’s TA Score shows that 3 TA indicator(s) are bullish while VANI’s TA Score has 4 bullish TA indicator(s).

  • SCNI’s TA Score: 3 bullish, 4 bearish.
  • VANI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both SCNI and VANI are a bad buy in the short-term.

Price Growth

SCNI (@Biotechnology) experienced а -28.28% price change this week, while VANI (@Biotechnology) price change was +0.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.67%. For the same industry, the average monthly price growth was -10.91%, and the average quarterly price growth was +1.00%.

Reported Earning Dates

VANI is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (-2.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
SCNI
Daily Signal:
Gain/Loss:
VANI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EDGX26.710.07
+0.26%
Global X U.S. 500 Income Edge ETF (EDGX)
CPRJ27.34N/A
-0.02%
Calamos Russell 2000 Structured Alt Protection ETF July (CPRJ)
EJAN37.17-0.07
-0.19%
Innovator Emerging Markets Power Buffer ETF January (EJAN)
VGSR10.62-0.05
-0.45%
Vert Global Sustainable Real Estate ETF (VGSR)
CWI40.41-0.32
-0.79%
State Street SPDR MSCI ACWI ex-US ETF (CWI)

VANI and

Correlation & Price change

A.I.dvisor indicates that over the last year, VANI has been loosely correlated with VTVT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VANI jumps, then VTVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VANI
1D Price
Change %
VANI100%
+0.81%
VTVT - VANI
60%
Loosely correlated
+2.80%
ADIL - VANI
37%
Loosely correlated
-3.37%
AXSM - VANI
36%
Loosely correlated
-0.94%
SCNI - VANI
34%
Loosely correlated
+0.71%
ANVS - VANI
33%
Poorly correlated
-2.31%
More